Page last updated: 2024-10-31

mitoxantrone and Allergic Encephalomyelitis

mitoxantrone has been researched along with Allergic Encephalomyelitis in 18 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

ExcerptRelevanceReference
"Mitoxantrone is a synthetic anthracenedione recently approved by the FDA for the treatment of worsening relapsing-remitting (RR), secondary progressive (SP), and progressive relapsing (PR) multiple sclerosis (MS)."8.82Review of mitoxantrone in the treatment of multiple sclerosis. ( Herndon, R; Jeffery, DR, 2004)
"Mitoxantrone has proved efficacy in treatment of multiple sclerosis (MS)."8.12Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats. ( Abdallah, DM; El Achy, S; El-Abhar, HS; El-Emam, MA; Gowayed, MA, 2022)
"Escalation therapy with mitoxantrone (MX) in highly active multiple sclerosis is limited by partially dose-dependent side-effects."7.75ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. ( Chan, A; Cotte, S; Dörr, J; Gold, R; Huber, B; Koepsell, H; König, N; Kruse, N; Lühder, F; Montalban, X; Pannek, H; Paul, F; Starck, M; Tellez, N; von Ahsen, N; Winkelmann, A; Zettl, UK; Zipp, F, 2009)
"The side effects of cancer chemotherapeutic agents such as mitoxantrone (MIT) in multiple sclerosis (MS) patients justify the search for less toxic drugs."7.74Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. ( Bai, XF; Campagnolo, DI; Dorr, RT; Huang, J; Piao, WH; Shi, FD; Vollmer, TL; Wong, R, 2007)
"Mitoxantrone, a new antineoplastic anthracenedione drug, suppressed the development of experimental allergic encephalomyelitis (EAE) in rats when administered during the incubation period."7.67Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. ( Levine, S; Saltzman, A, 1986)
"The effect of treatment with the antineoplastic, immunomodulatory agent mitoxantrone on the course of acute and relapsing experimental allergic encephalomyelitis (EAE) in the mouse has been studied."7.67Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. ( Knobler, RL; Lavasa, M; Lublin, FD; Viti, C, 1987)
"Treatment of rats with a developing or an established lesion of experimental allergic encephalomyelitis (EAE) with mitoxantrone (Novantrone) suppressed the hind limb paralysis associated with the disease."7.67Suppression of experimental allergic encephalomyelitis by mitoxantrone. ( Kerwar, SS; Levine, S; McReynolds, RA; Oronsky, AL; Ridge, SC; Sloboda, AE, 1985)
"Mitoxantrone is a synthetic anthracenedione recently approved by the FDA for the treatment of worsening relapsing-remitting (RR), secondary progressive (SP), and progressive relapsing (PR) multiple sclerosis (MS)."4.82Review of mitoxantrone in the treatment of multiple sclerosis. ( Herndon, R; Jeffery, DR, 2004)
"Mitoxantrone has proved efficacy in treatment of multiple sclerosis (MS)."4.12Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats. ( Abdallah, DM; El Achy, S; El-Abhar, HS; El-Emam, MA; Gowayed, MA, 2022)
"Previously we showed that BBR3378, a novel analog of the anticancer drug mitoxantrone, had the ability to ameliorate ascending paralysis in MOG35-55-induced experimental autoimmune encephalomyelitis (EAE), a murine model of human multiple sclerosis, without the drug-induced cardiotoxicity or lymphopenia associated with mitoxantrone therapy."3.83An aza-anthrapyrazole negatively regulates Th1 activity and suppresses experimental autoimmune encephalomyelitis. ( Clark, MP; Hazelhurst, LA; Hwang, ES; Leaman, DW; Quinn, A, 2016)
"Mitoxantrone is one of the few FDA-approved drugs available to treat rapidly progressing forms of multiple sclerosis; however, its utilization is compromised by a cardiotoxic potential and the risk of mitoxantrone-induced leukemia."3.77A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity. ( Gunning, W; Hacker, M; Kiraly, A; Koffman, B; Quinn, A; Rasche, S, 2011)
"Escalation therapy with mitoxantrone (MX) in highly active multiple sclerosis is limited by partially dose-dependent side-effects."3.75ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. ( Chan, A; Cotte, S; Dörr, J; Gold, R; Huber, B; Koepsell, H; König, N; Kruse, N; Lühder, F; Montalban, X; Pannek, H; Paul, F; Starck, M; Tellez, N; von Ahsen, N; Winkelmann, A; Zettl, UK; Zipp, F, 2009)
"The side effects of cancer chemotherapeutic agents such as mitoxantrone (MIT) in multiple sclerosis (MS) patients justify the search for less toxic drugs."3.74Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. ( Bai, XF; Campagnolo, DI; Dorr, RT; Huang, J; Piao, WH; Shi, FD; Vollmer, TL; Wong, R, 2007)
" To elucidate possible mechanisms behind such phenomena the effects were studied of mitoxantrone (Mx) and cyclosporin A (CsA) given at high and low doses on clinical course, and on autoreactive T- and B-cell responses in actively induced experimental allergic encephalomyelitis (EAE) in Lewis rats."3.68Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity. ( Diener, P; Link, H; Mustafa, M; Olsson, T; Sun, JB, 1993)
"Mitoxantrone was used as an immunosuppressive probe to elucidate a means for the control of experimental allergic encephalomyelitis (EAE) induced in Biozzi AB/H mice following injection of spinal cord homogenate emulsified in Freund's adjuvant."3.68Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone. ( Baker, D; Davison, AN; O'Neill, JK; Turk, JL, 1992)
"Mitoxantrone, a new antineoplastic anthracenedione drug, suppressed the development of experimental allergic encephalomyelitis (EAE) in rats when administered during the incubation period."3.67Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. ( Levine, S; Saltzman, A, 1986)
"The effect of treatment with the antineoplastic, immunomodulatory agent mitoxantrone on the course of acute and relapsing experimental allergic encephalomyelitis (EAE) in the mouse has been studied."3.67Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. ( Knobler, RL; Lavasa, M; Lublin, FD; Viti, C, 1987)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19903 (16.67)18.7374
1990's4 (22.22)18.2507
2000's7 (38.89)29.6817
2010's3 (16.67)24.3611
2020's1 (5.56)2.80

Authors

AuthorsStudies
El-Emam, MA1
El Achy, S1
Abdallah, DM1
El-Abhar, HS1
Gowayed, MA1
Clark, MP1
Leaman, DW1
Hazelhurst, LA1
Hwang, ES1
Quinn, A2
Cotte, S1
von Ahsen, N1
Kruse, N1
Huber, B1
Winkelmann, A1
Zettl, UK1
Starck, M1
König, N1
Tellez, N1
Dörr, J1
Paul, F1
Zipp, F1
Lühder, F1
Koepsell, H1
Pannek, H1
Montalban, X1
Gold, R2
Chan, A2
Kiraly, A1
Koffman, B1
Hacker, M1
Gunning, W1
Rasche, S1
Alves, CC1
Castro, SB1
Costa, CF1
Dias, AT1
Alves, CJ1
Rodrigues, MF1
Teixeira, HC1
Almeida, MV1
Ferreira, AP1
Weilbach, FX1
Toyka, KV1
Cavaletti, G1
Cavalletti, E1
Crippa, L1
Di Luccio, E1
Oggioni, N1
Mazzanti, B1
Biagioli, T1
Sala, F1
Sala, V1
Frigo, M1
Rota, S1
Tagliabue, E1
Stanzani, L1
Galbiati, S1
Rigolio, R1
Zoia, C1
Tredici, G1
Perseghin, P1
Dassi, M1
Riccio, P1
Lolli, F1
Webb, M1
Tham, CS1
Lin, FF1
Lariosa-Willingham, K1
Yu, N1
Hale, J1
Mandala, S1
Chun, J1
Rao, TS1
Jeffery, DR1
Herndon, R1
Neuhaus, O1
Kieseier, BC1
Hartung, HP1
Piao, WH1
Wong, R1
Bai, XF1
Huang, J1
Campagnolo, DI1
Dorr, RT1
Vollmer, TL1
Shi, FD1
Mustafa, M1
Diener, P1
Sun, JB1
Link, H1
Olsson, T1
Gonsette, RE1
Baker, D2
O'Neill, JK2
Davison, AN2
Turk, JL2
Watson, CM1
Levine, S2
Saltzman, A1
Lublin, FD1
Lavasa, M1
Viti, C1
Knobler, RL1
Ridge, SC1
Sloboda, AE1
McReynolds, RA1
Oronsky, AL1
Kerwar, SS1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)[NCT01627938]Phase 250 participants (Anticipated)Interventional2012-04-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for mitoxantrone and Allergic Encephalomyelitis

ArticleYear
Review of mitoxantrone in the treatment of multiple sclerosis.
    Neurology, 2004, Dec-28, Volume: 63, Issue:12 Suppl 6

    Topics: Animals; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunosuppre

2004
Mitoxantrone in multiple sclerosis.
    Advances in neurology, 2006, Volume: 98

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimenta

2006
Mitoxantrone immunotherapy in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 1996, Volume: 1, Issue:6

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Humans

1996

Other Studies

15 other studies available for mitoxantrone and Allergic Encephalomyelitis

ArticleYear
Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats.
    BMC neuroscience, 2022, 03-05, Volume: 23, Issue:1

    Topics: Animals; bcl-2-Associated X Protein; Encephalomyelitis, Autoimmune, Experimental; Forkhead Transcrip

2022
An aza-anthrapyrazole negatively regulates Th1 activity and suppresses experimental autoimmune encephalomyelitis.
    International immunopharmacology, 2016, Volume: 31

    Topics: Animals; Anthracyclines; Apoptosis; Autoimmunity; Cell Proliferation; Cytokines; Encephalomyelitis,

2016
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Brain : a journal of neurology, 2009, Volume: 132, Issue:Pt 9

    Topics: Adult; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Sub

2009
A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity.
    Clinical immunology (Orlando, Fla.), 2011, Volume: 141, Issue:3

    Topics: Animals; Autoimmunity; Cytokines; Disease Models, Animal; Disease Progression; Encephalomyelitis, Au

2011
Anthraquinone derivative O,O'-bis-(3'-iodopropyl)-1,4-dihydroxyanthraquinone modulates immune response and improves experimental autoimmune encephalomyelitis.
    International immunopharmacology, 2012, Volume: 14, Issue:2

    Topics: Animals; Cell Line; Cell Movement; Cell Survival; Cytokines; Encephalomyelitis, Autoimmune, Experime

2012
The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.
    Clinical and experimental immunology, 2004, Volume: 135, Issue:1

    Topics: Animals; Apoptosis; Cardiotonic Agents; Chelating Agents; Dose-Response Relationship, Drug; Drug The

2004
Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.
    Journal of neuroimmunology, 2004, Volume: 151, Issue:1-2

    Topics: Acute Disease; Animals; Cell Division; Cells, Cultured; Chronic Disease; Encephalomyelitis, Autoimmu

2004
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.
    Journal of neuroimmunology, 2004, Volume: 153, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Inter

2004
Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis.
    Journal of immunology (Baltimore, Md. : 1950), 2007, Dec-01, Volume: 179, Issue:11

    Topics: Acute Disease; Animals; Anthracenes; Antineoplastic Agents; Disease Models, Animal; Dose-Response Re

2007
Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity.
    Scandinavian journal of immunology, 1993, Volume: 38, Issue:6

    Topics: Animals; Antibody-Producing Cells; Autoimmunity; B-Lymphocytes; Brain; Cyclosporine; Down-Regulation

1993
Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.
    Clinical and experimental immunology, 1992, Volume: 90, Issue:1

    Topics: Animals; Blood-Brain Barrier; Encephalomyelitis, Autoimmune, Experimental; Immunosuppressive Agents;

1992
Suppression of demyelination by mitoxantrone.
    International journal of immunopharmacology, 1991, Volume: 13, Issue:7

    Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Immunosuppressive Agents; Leukocytes;

1991
Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone.
    Journal of neuroimmunology, 1986, Volume: 13, Issue:2

    Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Injections, Intraperitoneal; Injection

1986
Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone.
    Clinical immunology and immunopathology, 1987, Volume: 45, Issue:1

    Topics: Acute Disease; Animals; Encephalomyelitis, Autoimmune, Experimental; Immunization; Mice; Mice, Inbre

1987
Suppression of experimental allergic encephalomyelitis by mitoxantrone.
    Clinical immunology and immunopathology, 1985, Volume: 35, Issue:1

    Topics: Animals; Anthraquinones; Cyclophosphamide; Drug Administration Schedule; Encephalomyelitis, Autoimmu

1985